Bio-Pharm Archives - 17 중 4 번째 페이지

LG Chem Sells Aesthetics Business to Focus on Oncology

LG Chem fillers. [photo=LG Chem] LG Chem has sold its aesthetics business, including its hyaluronic acid (HA) fillers, for approximately KRW 200 billion (USD 144 million), shifting its strategic focus…

Cheon Okhyeon

2025-08-07

Hugel Reports Record-Breaking Q2 Results Fueled by Toxin and Filler Exports

Hugel posted its highest-ever quarterly earnings in the second quarter of 2025, driven by strong global demand for its botulinum toxin and hyaluronic acid (HA) filler products. The South Korea-based…

Cheon Okhyeon

2025-08-06

Celltrion Named Preferred Bidder for U.S. Plant to Address Tariff Risks

Celltrion has taken a major step to resolve tariff risks from the U.S. by pursuing the acquisition of a local production facility—a bold investment move. If the deal is finalized,…

Cheon Okhyeon

2025-07-29

Alteogen’s Eylea Biosimilar Clears EU Hurdle

Alteogen has cleared a major regulatory hurdle in its bid to enter the European biosimilar market. The Korean biopharmaceutical company announced on July 28 that the Committee for Medicinal Products…

Won Jonghyuck

2025-07-28

Daewoong Pharmaceutical Enters Biosimilar Race with Dupixent Candidate as First Pipeline

Daewoong Pharmaceutical is making a full-fledged entry into the biosimilar business as a new growth driver, bringing on board Dr. Seung-Seo Hong, a key figure in Celltrion’s biosimilar development. As…

Cheon Okhyeon

2025-07-22

Celltrion Reports Record Q2 Profit on Strong Sales of High-Margin Drugs

Celltrion achieved its highest-ever quarterly performance in the second quarter of 2025, fueled by robust sales of high-margin new products. On July 21, Celltrion announced provisional consolidated results for Q2…

Cheon Okhyeon

2025-07-21

Jay Y. Lee Acquitted After Decade-Long Trial, Renewing Focus on Samsung’s Bio Strategy

Samsung Electronics Chairman Jay Y. Lee has been cleared of all charges related to the controversial merger and accounting fraud allegations that have clouded his leadership for over a decade.…

Cheon Okhyeon

2025-07-17

Alteogen May Qualify for KOSPI…Management Holds the Key

Will Alteogen, a South Korean biopharmaceutical company, make the leap from KOSDAQ to KOSPI? The question has gained traction after Hyeong In-woo, the company's second-largest shareholder and CEO of Smart…

Cheon Okhyeon

2025-07-10

PharmaResearch Scraps Spin-Off Plan, Investors Cheer

PharmaResearch, a South Korean regenerative medicine company, has decided to scrap its planned spin-off, reversing course amid mounting shareholder opposition. The company had previously proposed a transition to a holding…

Cheon Okhyeon

2025-07-08

“Beyond Biosimilars”…Celltrion Moves into New Drug Development

Celltrion is accelerating its transition from a biosimilar-focused strategy to full-scale new drug development. With successive approvals for clinical trial applications (INDs) in Korea and abroad, the company is rapidly…

Cheon Okhyeon

2025-07-07